United States: FDA Draft Guidance On Indications And Usage Labeling

On July 6, 2018, the U.S. Food and Drug Administration (FDA) issued draft guidance to assist applicants in writing the Indications and Usage section of labeling for human prescription drug and biological products, "Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products—Content and Format," Draft Guidance for Industry (July 2018) ("Draft Guidance").3 FDA's recommendations in the Draft Guidance are intended to help ensure that the Indications and Usage section of labeling is "clear, concise, useful, and informative and, to the extent possible, consistent within and across drug and therapeutic classes." Id. at 2. The Draft Guidance supplements FDA's labeling rules and guidances.4 First, the Draft Guidance provides general principles to consider when drafting the Indications and Usage section of labeling.5 According to FDA, "[t]he primary role of the Indications and Usage section ... is to enable health care practitioners to readily identify appropriate therapies for patients by clearly communicating the drug's approved indication(s)." Id. at 2. "Other sections of labeling (e.g., Dosage and Administration, Contraindications, Warnings and Precautions, Use in Specific Populations) ... also provide essential details that enable safe and effective use of a drug, and labeling should be considered in its entirety for individual prescribing decisions." Id. FDA cautions, however, that "[i]ndications or uses must not be implied or suggested in other sections of the labeling if not included" in the Indications and Usage section. Id. at 3 (quoting 21 C.F.R. § 201.57(c)(2)(iv), (v)). Additionally, FDA may require a specific warning in the Warnings and Precautions section of the labeling to address unapproved uses "if the drug is commonly prescribed for a disease or condition and if such usage is associated with a clinically significant risk or hazard." Id. (citing 21 C.F.R. § 201.57(c)(6)(i)).

Second, the Draft Guidance discusses what information to include in the Indicat ions and Usage section. Id. at 6-14. According to FDA, the section "must state that the drug is indicated for the treatment, prevention, mitigation, cure, or diagnosis of a recognized disease or condition, or of a manifestation of a recognized disease or condition, or for relief of symptoms associated with a recognized disease or condition." Id. at 8 (quoting 21 C.F.R. § 201.57(c)(2)). The disease, condition, or manifestation should be referred to using high-level, clinically relevant terms that are well understood and easily recognized by health care practitioners. Id. Additionally, other information necessary to describe the approved indication, when applicable, should be identified. Id. at 7, 8-9. For example, descriptors or qualifiers of the population to be treated, such as approved age groups, patients previously treated with other therapies, or patients with a certain classification of the disease, may be important to include. Id. at 7, 8. The Indications and Usage section may also provide information about adjunctive or concomitant therapy, or specific tests needed for patient selection. Id. at 7, 9.

The Draft Guidance also states that limitations of use, which are presented separately from the indication within the Indications and Usage section, should be included "when there is reasonable concern or uncertainty among FDA's expert reviewers ... about a drug's risk-benefit profile" and "the awareness of such information is important for practitioners to ensure the safe and effective use of the drug." Id. at 10. FDA distinguishes limitations of use from contraindications, which are "situations in which the drug should not be used because the risk of use ...clearly outweighs any possible therapeutic benefit," and recommends avoiding redundancy in the labeling by not restating contraindications as limitations of use in the Indications and Usage section. Id. (quoting 21 C.F.R. § 201.57(c)(5)). FDA also recommends incorporating "information that essentially narrows or further defines a drug's approved indication and is used to direct appropriate therapy ... directly into the indication whenever possible," rather than including it as a limitation of use. Id. Limitations of use may be appropriate if there is reasonable concern or uncertainty about a drug's effectiveness or safety in a certain clinical situation; if a drug is approved without evidence of benefits known to occur with other drugs in the same class; or if a drug has certain dose, duration, or long-term use considerations. Id. at 11-13. Limitations of use would generally not be appropriate, however, to restate information already included in the indication or to address the absence of data in populations in which the drug was not studied. Id. at 13-14.

Third, the Draft Guida nce makes recommendations about how to write, organize, and format the information within the Indications and Usage section. Id. at 14-17. FDA states that while a full description of how benefits of treatment were measured in clinical trials is generally unnecessary, a broad disease indication may be inappropriate where the drug affects only certain signs, symptoms, or manifestations of a disease. Id. at 14. The Indication and Usage section may include an indication identifying outcomes or endpoints when, for example, "the drug's effect on the overall disease is not well understood; when different drugs have different effects on various manifestations of the diseases; when clinical trials evaluated only one or some of the manifestations of the disease; or when endpoints are different from the typical effectiveness measure." Id. Additionally, governing statutory and regulatory provisions require or recommend language for certain products, such as systemic antibacterial drug products and products containing a single enantiomer of a previously approved racemic drug. Id. at 15. FDA notes that the phrase "reduce the risk of" is generally preferable to the word "prevent," and that the words "only" and "also indicated" should generally not be used. Id. at 16.

Readers are encouraged to read the Draft Guidance in its entirety, as well as FDA's re lated rules and other guidances, and to consult with legal counsel when making decisions about their product labeling.

Footnote

3 Notice of Availability, 83 Fed. Reg. 31759 (July 9, 2018); "Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products—Content and Format," Draft Guidance for Industry (July 2018), https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm612697.pdf ("Draft Guidance") at 1.

4 See, e.g., "Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products," 71 Fed. Reg. 3922 (Jan. 24, 2006).

5 Draft Guidance at 2-6.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

1 Oct 2018, Seminar, New York, United States

Finnegan partner Doug Rettew will consider recent Internet Corporation for Assigned Names and Numbers (ICANN) developments during Practicing Law Institute’s Intellectual Property Institute.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions